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Abstract: Cornelia de Lange syndrome (CdLS) is a congenital developmental disorder 
characterized by distinctive craniofacial features, growth retardation, cognitive impairment, 
limb defects, hirsutism, and multisystem involvement. Mutations in five genes encoding 
structural components (SMC1A, SMC3, RAD21) or functionally associated factors (NIPBL, 
HDAC8) of the cohesin complex have been found in patients with CdLS. In about 60%  
of the patients, mutations in NIPBL could be identified. Interestingly, 17% of them are 
predicted to change normal splicing, however, detailed molecular investigations are often 
missing. Here, we report the first systematic study of the physiological splicing of the 
NIPBL gene, that would reveal the identification of four new splicing isoforms ΔE10, 
ΔE12, ΔE33,34, and B’. Furthermore, we have investigated nine mutations affecting  
splice-sites in the NIPBL gene identified in twelve CdLS patients. All mutations have been 
examined on the DNA and RNA level, as well as by in silico analyses. Although patients 
with mutations affecting NIPBL splicing show a broad clinical variability, the more severe 
phenotypes seem to be associated with aberrant transcripts resulting in a shift of the 
reading frame. 
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1. Introduction 
Cornelia de Lange syndrome (CdLS; OMIM 1227470, 300590, 610759, 614701, 300882) is  
a congenital developmental disorder characterized by distinctive craniofacial features, growth 
retardation, cognitive impairment, limb defects, hirsutism, and abnormalities of other systems with 
variable expressivity [1]. Mutations in five genes, encoding structural components of the cohesin 
complex (SMC1A, SMC3, and RAD21) and its regulators (NIPBL and HDAC8) have been found in 
patients with CdLS [2–9]. Cohesin was originally described for its function in regulating sister 
chromatid cohesion during mitosis and meiosis, but have also been demonstrated to play a critical role 
in DNA-damage repair and the regulation of gene expression [3]. 
Approximately 60% of patients with CdLS carry an identifiable mutation in NIPBL [2,4,5].  
This gene is located on chromosome 5p13.2 and contains 47 exons. Thus far, only two splicing  
isoforms have been detected in embryonic tissues, although there may be more variants due to the 
large size of NIPBL [10,11]. In the main isoform (A), exons 2–47 codify for 2804 amino acids.  
The alternative isoform (B) does not include exon 47 and ends in an expanded variant of exon 46, 
codifying for 2697 amino acids. Both isoforms are conserved in vertebrates and are identical  
from amino acid 1 to 2683, while the C-terminal ends are different [11–13]. 
Currently, nearly 300 mutations in NIPBL gene have been reported, 49 of which affect splice-sites, 
representing 17% of total mutations [14,15]. However, systematic investigations on physiological 
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splicing have not been evaluated in most of the cases. While truncating mutations are usually associated 
with a severe phenotype, and non-truncating mutations with a mild phenotype, clinical manifestations 
observed in patients with splicing mutations are highly variable in CdLS [4,16]. 
In this article, we have performed the first systematic analysis of the physiological splicing of 
NIPBL, which has yielded four new splicing variants. In addition, we have characterized the pathological 
splicing on twelve CdLS patients, in which we have identified seven new splicing mutations.  
This study was carried out using various molecular approaches on DNA, on RNA and in silico analyses. 
2. Results 
2.1. Clinical Findings 
Clinical evaluation by at least two expert clinicians of all patients included in this study confirmed 
they meet the criteria for CdLS according to Kline et al. [1]. Molecular and clinical data relative to 
each patient are summarized in Table 1. 
2.2. Aberrant Splicing Caused by NIPBL-Mutations 
By targeted Sanger sequencing of all 47 exons of the NIPBL gene we could identify nine allelic 
variants in our patients (Figure 1, Table 1) situated into the exon-intron junctions. Two of these 
variants have been previously reported: c.3856-5delT and c.6109-3T>C [14,17,18], while seven are 
new: c.358+1G>A, c.869-2A>G, c.4320+4A>G, c.5328+1G>A, c.5329-6T>G, c.5575-1G>A, and 
c.7860+5G>A. All of them were intronic, and four mapped into canonical AG/GT nucleotides 
affecting the conserved splice-donor or acceptor-site, respectively. The other five variants affected 
non-canonical nucleotides, from −6 to +5 positions. 
The relevance of all nine splice-site mutations identified was investigated by specific RT-PCR 
using RNA isolated from fresh blood samples in order to identify aberrant splicing variants. 
Patients 1 and 2 showed two transcripts (Figure 1), the normal band of 743 bp and another band of 
615 bp corresponding to a deletion of exon 4. Patients 3A and 3B showed two transcripts, the normal 
band of 824 bp and another band of 197 bp consistent with a deletion of exon 9. Patient 4 showed  
two transcripts (Figure 1), the normal band of 449 bp and another band of 217 bp consistent with  
an exon 17-deletion. Patient 5 showed one PCR product (Figure 1), which contained both the normal 
transcript of 505 bp, and the aberrant transcript of 509 bp containing a 4 bp insertion at 3' end of  
exon 19. Patient 6 showed two transcripts (Figure 1), the normal band of 392 bp and another band of 
289 bp representing an exon 27-deletion. Patient 7A showed two transcripts (Figure 1), the normal 
band of 304 bp and another band of 205 bp excluding exon 28. Patient 8 showed one PCR product 
(Figure 1), which contained both the normal transcript of 314 bp, and the aberrant transcript of 313 bp 
that shows a 1 bp deletion at exon 30 5' end. Patient 9 showed one PCR product of 578 bp (Figure 1) 
representing the normal transcript. Patient 10 was analyzed for isoforms A and B (Figure 1). In both, 
an aberrant transcript that contains a 33 bp deletion at 5' end of exon 45 in addition to the normal 
transcript could be detected. Moreover, also the transcript variant B’ was identified. 
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Table 1. Summary of molecular and clinical information in patients with splice site mutations. 
Patient Mutation Intron mRNA Change In Silico Analysis Predicted Protein Change Clinical Data 
P1 c.358+1G>A 4 
Exon 4 skipping 
(128 bp) 
Donor site 
disruption 
p.(Ile77Metfs*5) 
2-year-old boy with pre and postnatal growth 
retardation, developmental delay, typical facial 
features, heart valve stenosis and a feeding disorder. 
P2 c.358+1G>A 4 
Exon 4 skipping 
(128 bp) 
Donor site 
disruption 
p.(Ile77Metfs*5) 
13-year-old boy with pre and postnatal growth 
retardation, intellectual disability with speech and 
motor delay, typical facial features, aortic stenosis 
and hirsutism. 
P3A c.869-2A>G 8 
Exon 9 skipping 
(627 bp) 
Acceptor site 
disruption 
p.(Gly290_Lys498del) 
3-year-old boy with pre and postnatal growth 
retardation, intellectual disability with speech and 
motor delay, typical facial features, autistic 
spectrum disorders, a feeding disorder, 
cryptorchidism and hirsutism. 
P3B c.869-2A>G 8 
Exon 9 skipping 
(627 bp) 
Acceptor site 
disruption 
p.(Gly290_Lys498del) 
36-year-old female with postnatal growth 
retardation, typical facial features, a feeding 
disorder, minor skeletal anomalies and hirsutism. 
P4 
c.3856-5delT 
[18] 
16 
Exon 17 skipping 
(232 bp) 
Acceptor site 
disruption 
p.(Asn1286Glufs*3) 
23-year-old male with pre and postnatal growth 
retardation, typical features, intellectual disability, 
pyloric stenosis and a feeding disorder. 
P5 c.4320+4A>G 19 
Insertion of 4 pb at 
3' end of exon 19 
Donor site 
disruption and 
creation of a new 
cryptic donor site 
p.(Phe1442Serfs*5) 
7-year-old boy with postnatal growth retardation, 
intellectual disability with speech delay, typical 
facial features, deafness, GERD with a feeding 
disorder and small hands. 
P6 c.5328+1G>A 27 
Exon 27 skipping 
(103 bp) 
Donor site 
disruption 
p.(Met1743Serfs*16) 
4-year-old boy with pre and postnatal growth 
retardation, developmental delay, typical facial 
features, pulmonar stenosis, cryptorchidism, 
bilateral aplasia of the ulna, dysplasia of distal 
humerus and monodactyly. 
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Table 1. Cont. 
Patient Mutation Intron mRNA Change In Silico Analysis Predicted Protein Change Clinical Data 
P7A c.5329-6T>G 27 
Exon 28 skipping 
(99 bp) 
Acceptor site 
disruption 
p.(Ile1777_Arg1809del) 
9-year-old boy with has pre and postnatal growth 
retardation, intellectual disability with speech 
delay, typical facial features, hirsutism and  
small hands. 
P7B c.5329-6T>G 27 
Exon 28 skipping 
(99 bp) 
Acceptor site 
disruption 
p.(Ile1777_Arg1809del) 
40-year-old male with typical features, intellectual 
disability, hearing loss, ventricular septal defect  
and crytorchidism. 
P8 c.5575-1G>A 29 
Loss of 1 pb at  
5' end of exon 30 
Acceptor site 
disruption and 
creation of a new 
acceptor site 
p.(Asp1859Ilefs*9) 
1-year-old girl with pre and postnatal growth 
retardation, typical facial features, left ventricular 
hypertrophy, feeding disorder, horseshoe kidney, 
hirsutism, right amelia and small feet. 
P9 
c.6109-3T>C 
[16−18] 34 No effect 
Maintenance of 
acceptor site 
strengh 
No effect 
26-year-old female with pre and postnatal growth 
retardation, intellectual disability with speech 
delay, typical facial features, deafness, feeding 
disorder, hirsutism, small hands and feet. 
P10 c.7860+5G>A 45 
Loss of 33 pb at  
3' end of exon 45 
Donor site 
disruption and 
activation of  
a cryptic donor site 
p.(Val2610_Asp2620del) 
8-year-old girl with speech delay, typical facial 
features and a feeding disorder. 
Abbreviation: GERD, Gastroesophageal Reflux Disease; P1: Patient 1; P2: Patient 2; P3A: Patient 3A; P3B: Patient 3B; P4: Patient 4; P5: Patient 5; P6: Patient 6; P7A: 
Patient 7A; P7B: Patient 7B; P8: Patient 8; P9: Patient 9; P10: Patient 10. 
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Figure 1. Overview about the localization of the mutations and its consequence upon 
transcript processing. Mutations are represented on isoform A. Boxes mean exons and  
dark lines mean introns. Dark boxes represent the untranslated region. The main functional 
domains in exons affected by splicing mutations are highlighted in violet (Undecapeptide 
repeat, H1 and H2 repeats in the HEAT (Huntington, Elongation Factor 3, PR65/A, TOR) 
domain). The localization of each mutation is shown above the gene, and their effect on 
splicing is shown under the gene. Dotted lines represent the aberrant splicing, and agarose 
gels with the analysis of the cDNA are shown. (MW: Molecular Weight, WT: Wild-Type, 
P1: Patient 1, P2: Patient 2, P3A: Patient 3A, P3B: Patient 3B, P4: Patient 4, P5: Patient 5, 
P6: Patient 6, P7A: Patient 7A, P7B: Patient 7B, P8: Patient 8, P9: Patient 9, P10:  
Patient 10). 
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Among the aberrant transcripts found, five cause a frameshift (patients 1, 2, 4, 5, 6, and 8), whereas 
three preserve the reading frame (Patients 3A, 3B, 7A, 7B, and 10) (Figure 1, Table 1). 
The effect of all mutations was evaluated in silico with the programs Splice Site Prediction by 
Neural Network, HSF Matrices and MaxEnt [19,20]. 
For mutations located in the canonical position +1, which resulted in exon skipping, donor site 
disruption was confirmed (Table 1) with the three different programs used. 
For c.5575-1G>A, which causes a loss of the first bp of exon 30, the three programs confirmed  
the disruption of the acceptor sequence, and predicted the generation of a new acceptor site one 
nucleotide downstream (Table 1). 
For the rest of acceptor site mutations, in c.869-2A>G, c.3856-5delT, and c.5329-6T>G that 
resulted in exon skipping, acceptor site disruption was predicted (Table 2). However, the change 
c.6109-3T>C, which only showed the normal transcript, barely modified the acceptor site score 
strength (Table 2). 
For donor site mutations, c.4320+4A>G leads to the insertion of four bps after exon 19. This 
mutation disrupted the original donor site in exon 19, but HSF Matrices and MaxEnt predicted  
the creation of a new one, four positions downstream (Table 1). In exon 45, the mutation 
c.7860+5G>A, which caused the deletion of 33 bp at the 3' end, disrupted the original donor site, but a 
cryptic donor sequence was found 33 nucleotides upstream (Table 1). 
2.3. New Physiological Splicing Variants of NIPBL 
Using various combinations of different oligonucleotides specifically aligning to diverse exons in 
NIPBL, five splice variants could be amplified and confirmed on cDNA level (Figure 2b, Table 2). 
Interestingly, only one of which has been described as isoform B, while the remaining four have not 
been reported. All four new variants are the result of whole exon skipping, affecting exons 10, 12,  
33 + 34, or 45. They have been submitted to GenBank, with the following accession numbers: 
KJ807789, KJ807790, KJ807791, and KJ807792. 
Table 2. Splicing variants found in NIPBL. 
Splicing 
Variant 
mRNA Change 
In Silico 
Analysis 
Predicted Protein Change 
ΔE10 Exon 10 skipping (1646 bp)  
c.1496_3121del 
Exon 10 weak 
acceptor site 
p.(Asp499_Lys1040del) 
ΔE12 Exon 12 skipping (198 bp)  
c.3305_3502del 
Exon 12 weak 
acceptor site 
p.(Ser1102_Val1168delinsPhe) 
ΔE33,34 Exons 33 and 34 skipping (246 bp)  
c.5863_6108del 
Exon 33 weak 
acceptor site 
p.(Leu1955_Ser2036del) 
B 
Exon 47 skipping (365 bp)and 
introduction of 211 bp of intron 46  
c.8050_8415delins42 
Exon 47 weak 
acceptor site 
p.(Ser2864_Ser2904delinsValfs*13) 
B’(ΔE45) 
Exons 45 (175 bp) and 47 (365 bp) skipping 
and introduction of 211 bp of intron 46  
c.[7686_7861del(;)8050_8415delins42] 
Exons 45 and 
47 weak 
acceptor site 
p.(Lys2563Serfs*63) 
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Figure 2. Systematic analysis of the physiological splicing of NIPBL. (a) Schematic 
representation of the two isoforms of the NIPBL gene and the three strategies used for  
the analysis of the physiological splicing. Boxes represent the exons and dark lines 
represent the introns. Exons 1–47 are shown for isoform A, and exons 44–46B are shown 
for isoform B. Dark boxes represent the untranslated region. The main functional domains 
are highlighted in violet (Undecapeptide repeat, Nuclear Localization Signal, H1–H5 
domains in the HEAT repeats). Analysis of the physiological splicing has been performed 
amplifying the gene into four fragments (A–D, light green); into eight fragments (A1–D2, 
medium green); and into 23 fragments (F1–F23, dark green). F22B was used to specifically 
detect isoform B; (b) Physiological splicing variants of NIPBL found in human leukocytes. 
Four new variants with whole exon deletion have been found. Representative agarose gels 
are shown for each variant (WT: Wild-Type; ΔE10: exon 10 deletion; ΔE12: exon 12 
deletion; ΔE33,34: exon 33 + 34 deletion; B’: exon 45 deletion on isoform B). 
 
While the skipping of exons 10, 12, and 33 + 34 preserve the reading frame, loss of exon 45 cause  
a frameshift, as seen in variants B and B’ (Figure 2b, Table 2). A deletion of exon 10 (ΔE10) was 
found in amplifications B, B1, and F5. Deletion of exon 12 (ΔE12) was found in amplifications B1, 
B2, and F6 and skipping of the exons 33 + 34 (ΔE33 + 34) could be detected in amplifications C and 
C2. The deletion of exon 45 (ΔE45) was found in amplification F22B, specific for the known NIPBL 
isoform B, and defined as the new isoform B’. Specific amplification of the known NIPBL isoform A 
could not detect skipping of exon 45 (Figure 2b). 
The strength of the exons involved in physiological splicing was evaluated using Splice Site 
Prediction by Neural Network. Exons 10, 12, 33, 45, and 47 showed very low acceptor site scores: 
(exon 10: 0.49, exon 12: 0.00, exon 33: 0.15, exon 45: 0.00, and exon 47: 0.41), and strong donor site 
scores (exon 10: 1.00, exon 12: 0.92, exon 33: 0.98, and exon 45: 0.96). Exon 34 was a well-defined 
exon, with acceptor and donor sites scores of 0.90 and 0.98, respectively (Table 2). 
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3. Discussion 
In this work, we describe the first coordinated analysis of twelve CdLS–causing splice-site 
mutations in the NIPBL gene on DNA and RNA level as well as by in silico analyses. In order to 
properly assess aberrant splicing, we initially investigated the physiological NIPBL-splicing using 
RNA isolated from human leukocytes of normal controls. 
Currently, two NIPBL splicing isoforms have been found in embryonic human tissues. Isoform  
A encodes a 2804 amino acid protein, while isoform B differs at in the 3'-part and codes for a 2697 aa 
NIPBL protein [12]. By our analyses we could identify and confirm the presence of four new isoforms 
(splice variants) in addition to isoform A and B in adult human leukocytes. One of these new isoforms, 
named Isoform B’, represents a transcript similar to isoform B excluding exon 45 which results in  
a shift of the reading frame. Systematic amplification of overlapping fragments could describe  
three new variants, carrying a deletion of exon 10 (ΔE10), exon 12 (ΔE12), and exons 33 + 34 
(ΔE33,34), respectively (Figure 2b, Table 2). These findings were further supported by different  
in silico analyses indicating very weak splice acceptor-sites of exons 10, 12, 33, 45, and 47 (Table 2), 
with the exception of splice acceptor-site exon 34, which was predicted as strong splice-site [21].  
We could show a combined skipping of exon 34 with the weak exon 33, which may drag the strong 
exon 34 during the splicing process, as previously reported for other genes [22,23]. 
Variants with deletion of exon 10, exon 12, and exons 33 + 34 maintain the reading frame, and 
could lead to functional proteins. The deletions of exons 10 and 12 affect the amino-terminal half of  
the gene, which is highly conserved in evolution [11]. However, the deletion of exons 33 + 34 affects 
the ancient carboxy-terminal half, which is conserved due to lower eukaryotes. Bioinformatic analyses 
suggest that variant ΔE10 could affect the undecapeptides repeat, which has been associated with 
transcriptional regulation; while variant ΔE12 would eliminate the predicted nuclear localization signal 
(NLS) of this protein [24]. On the other hand, variant ΔE33,34 would provoke the loss of the H3 
domain in the HEAT repeats, which plays an important role in the interactions between NIPBL and  
the histone deacetylases (HDACs) 1 and 3 (Figure 2b) [25]. 
Among the twelve patients studied, we have detected nine splice-sites mutations, seven of them 
new, which represent 14% of the splicing mutations reported to date (Figure 1, Table 1). This kind of 
mutations show a random distribution across NIPBL, unlike nonsense and missense mutations, which 
tend to accumulate respectively in the first or in the last half of the gene [4,11]. 
Splicing mutations can result in different effects [26]. The most common is the skipping of the next 
exon. Here, this phenomenon has been found in mutations located in canonical nucleotides (c.358+1G>A, 
c.869-2A>G, and c.5328+1G>A), as well as in mutations affecting the polypyrimidine-rich tract  
(c.3856-5delT y c.5329-6T>G) (Table 1, Figure 1) [27]. 
Sometimes, splicing mutations can provoke the partial loss of the exon by activating cryptic splice 
sequences [28]. An example would be the mutation c.7860+5G>A, which disrupts the splicing donor 
sequence in exon 45. In this case, we would expect whole exon deletion, since exon 45 contains  
a weak acceptor sequence and skips physiologically yielding the variant B’ (Figure 2b). However,  
we have found an aberrant transcript with the deletion of 33 nucleotides at the 3' end of exon 45 
(Figure 1). Bioinformatic analyses could predict a cryptic donor sequence at this position that is 
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activated by the disruption of the original donor sequence (Table 1) [29]. Moreover, the mutation 
c.7860+5G>A could affect the ratio of physiological transcripts [23]. 
Eventually, splicing mutations can disrupt the original splice-sites and generate new ones [30,31], 
like in the mutations c.4320+4A>G (patient 5) and c.5575-1G>A (patient 8) (Figure 1, Table 1).  
In patient 5, an expansion of four nucleotides in exon 19 could be observed that disrupted the reading 
frame. This is in contrast to similar mutations previously reported (c.4320+2T>A and c.4320+5G>C), 
that result in an in frame skipping of exon 19 [4,32]. In patient 8, the mutation c.5575-1G>A was 
expected to cause the skipping of exon 30. Instead, it has generated an aberrant transcript corresponding 
to the deletion of the first nucleotide of exon 30. In silico tools predict that both mutations create new 
functional splice sites that were confirmed by sequencing of aberrant transcripts (Table 1). 
Among the mutations analyzed here, c.6109-3T>C has not been considered as a functional  
splicing mutation since it has not generated aberrant transcripts (Figure 1), and was inherited from the 
healthy mother. Interestingly, this sequence variation has been previously reported in four CdLS  
patients [16–18] but was suggested to be not relevant for splicing by Leiden Open Variant  
Database (LOVD) [33]. 
Three of the splicing mutations analyzed here have produced transcripts with in frame deletions 
(c.869-2A>G (P3A and P3B), c.5329-6T>G (P7A and P7B), c.7860+5G>A (P10)), while five 
mutations have generated aberrant transcripts disrupting the reading frame (c.358+1G>A (P1 and P2), 
c.3856-5delT (P4), c.4320+4A>G (P5), c.5328+1G>A (P6) y c.5575-1G>A (P8)) (Figure 2).  
In NIPBL, frameshift mutations are often associated with more severe phenotypes as compared to 
mutations preserving the reading frame [4,15,16]. Splicing mutations identified in our patients seem to 
follow this tendency except patient 5 (c.4320+4A>G), who was classified as mild (Table 2). Thus, 
patients 1, 2, 4, 6, and 8 show severe pre- and postnatal growth delay, and P6 and P8 also show severe 
structural anomalies of the limbs (Table 1). Recently, in frame deletions and missense mutations 
affecting the HEAT domains have also been associated with severe phenotypes [15]. However, 
although patients 7A and 7B show an aberrant transcript with in frame deletion of a great part of the 
H1 domain, they had a mild phenotype with intellectual disability (Table 1). 
4. Experimental Section 
4.1. Patients and Controls 
This study includes twelve patients diagnosed following the criteria from Kline et al. [1]. There are 
eight patients from Germany, and two familial cases, one from Poland (patients 3A and 3B, son and 
mother) and the other one from Spain (patients 7A and 7B, son and father). In accordance with the 
Declaration of Helsinki, the study had been approved by the ethics committee of the University of 
Lübeck, on November 2007 (reference number: 07-158). Patients’ parents have written individual 
informed consent to participate in the study. To perform the experiments, a pool of four control cDNAs 
from normal subjects was used. 
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4.2. DNA Extraction and Sequence Analysis 
Genomic DNA was extracted from peripheral blood leukocytes using the standard procedures.  
The primers used to amplify the exons of the NIPBL gene and their splice junctions are provided on 
request. The PCR products obtained were purified with USB ExoSAP-IT PCR Product Cleanup 
(Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s instructions, and sequenced on 
an ADN 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 
The nucleotides of NIPBL cDNA were numbered according to the NIPBL isoform 1 (GenBank 
accession No. NM_000642). The mutation nomenclature was designated according to the Human 
Genome Variation Society [34] and confirmed by Mutalyzer [35]. In order to make data publicly 
available, mutations and associated phenotypic information were submitted to the Leiden Open Variant 
Database, Leiden, The Netherlands [14]. 
4.3. RNA Extraction and cDNA Synthesis 
RNA was extracted from blood leukocytes using the PAXgene Blood RNA Kit (PreAnalytiX 
GmbH, Hombrechtikon, Switzerland) according the manufacturer’s instructions. Single-stranded 
cDNAs were synthesized with 500 ng of RNA from each patient using the First Strand Synthesis  
Kit (Thermo Fisher Scientific Inc, Waltham, MA, USA) with random hexamers, following the 
manufacturer’s protocol. 
4.4. Identification of Splicing Variants 
Physiological splicing variants were obtained using cDNA from a pool of four control individuals. 
Total NIPBL cDNA was amplified by PCR in overlapping fragments using three different approaches: 
dividing NIPBL into 4 fragments (A, B, C, and D), 8 fragments (A1, A2, B1, B2, C1, C2, D1, and D2), 
and 23 fragments (F1–F23). In this last strategy, an additional PCR (F22B) was performed to 
specifically amplify the isoform B (Figure 2a). Primers are provided on request. 
To evaluate the aberrant splicing caused by mutations found in the NIPBL gene, specific PCRs that 
amplified the exons surrounding the mutations were performed on cDNA of each patient. Primers used 
are provided on request. The same reactions were carried out on cDNA from peripheral blood from  
a control individual. 
For each PCR reaction, 2 μL of cDNA were used as a template in a total 20-μL mixture. 
Amplifications were carried out using 10 pmol of each PCR primer, 1× reaction buffer, 1.5 mM 
Mg2SO4, 200 μM dNTPs and 0.5 U Taq DNA polymerase. PCRs were performed in a thermocycler 
(Applied Biosystems) for 35 cycles at an annealing temperature of 56 °C. 
PCR products obtained were analyzed by electrophoresis in 2% agarose gels, and all the bands  
were excised and purified with QIAEX Gel Extraction Kit (QIAGEN, Hilden, Germany), or purified 
with USB ExoSAP-IT PCR Product Cleanup (Affymetrix) when there was only a single band.  
The identity of each band was confirmed by sequencing on an ADN 3130 Genetic Analyzer  
(Applied Biosystems). 
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4.5. In Silico Splicing Analysis 
First, we analyzed all NIPBL wild-type and mutated exons with Splice Site Prediction by Neural 
Network [19,36]. This bioinformatic tool assigns a strength score from 0.00 to 1.00 to acceptor (3' ss) 
and donor (5' ss) splice sites of each exon. It was used to evaluate the strength of affected exons, to 
predict disruption or creation of splice sites and to identify potential cryptic splice sites. 
Later, we used a variety of tools integrated in the Human Splicing Finder [20] to perform a  
more exhaustive analysis of the exons affected by physiological/aberrant splicing. HSF [37] and 
MaxEnt [38] are tools that predict splice sites strength and can complement the data obtained from 
Splice Site Prediction by Neural Network. 
5. Conclusions 
In this study, he have performed the first systematic study of the physiological splicing of the 
NIPBL gene, that has allowed us to identify four new variants ΔE10, ΔE12, ΔE33,34, and B’,  
which should be kept in mind in order to assess the pathological splicing (Figure 2b). In addition,  
we have characterized eight splicing mutations, seven of which new, that means 14% of the reported 
mutations. The analysis of the RNA has ruled out that c.6109-3T>C is a splicing mutation, so its 
pathogenicity mechanism remains unclear (Figure 1). We also have confirmed that among the broad 
clinical variability that show the splicing mutations, the more severe phenotypes seem to associate to 
mutations generating frameshift transcripts. 
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